CYP27B1

Vitamin D does not actually do anything in your body until a specific enzyme converts it into its active form. The gene that builds that enzyme is called CYP27B1, and small variations in its DNA can change how efficiently your body activates vitamin D and how that may influence your long-term risk for autoimmune disease, certain cancers, and bone problems.

Testing your CYP27B1 variants gives you a one-time look at the genetic hand you were dealt. The result will not change over your lifetime, but it can inform how you think about vitamin D supplementation, autoimmune surveillance, and family planning if there is a history of disorders linked to vitamin D activation.

What This Gene Does

CYP27B1 (cytochrome P450 family 27 subfamily B member 1) builds an enzyme called 1-alpha-hydroxylase. That enzyme takes the storage form of vitamin D that circulates in your blood (called 25-hydroxyvitamin D, or 25(OH)D for short) and converts it into the active form, called 1,25-dihydroxyvitamin D or calcitriol. Most of this conversion happens in your kidneys, but immune cells, the placenta during pregnancy, and many other tissues can do it locally too.

Common one-letter changes in the gene (called single nucleotide polymorphisms, or SNPs, which are small DNA differences between people) can shift how much enzyme your body produces or how well that enzyme works. Some variants modestly raise risk for certain diseases. Rare, severe mutations on both inherited copies of the gene cause a childhood bone disease called vitamin D-dependent rickets type 1.

Type 1 Diabetes Risk

The clearest disease link for common CYP27B1 variants is autoimmune type 1 diabetes. A large case-control study found that inherited variation in CYP27B1 is associated with a higher risk of type 1 diabetes. A follow-up analysis pooling thousands of participants confirmed that variation in vitamin D pathway genes, including CYP27B1, contributes to type 1 diabetes susceptibility.

If you carry a CYP27B1 risk variant and have a family history of type 1 diabetes, that is a reason to take blood sugar and autoimmune marker monitoring seriously, especially in childhood and young adulthood.

Other Autoimmune Conditions

CYP27B1 variants have been repeatedly tied to autoimmune diseases beyond type 1 diabetes. A meta-analysis of vitamin D pathway gene polymorphisms found that two CYP27B1 variants (rs10877012 and rs4646536) influence susceptibility to organ-specific autoimmune endocrine diseases. A UK study identified a CYP27B1 promoter haplotype linked to autoimmune Addison's disease, where the adrenal glands stop making enough hormones. Systematic reviews have connected CYP27B1 variants to multiple sclerosis, rheumatoid arthritis, and systemic lupus. A study of people with multiple sclerosis (MS) recently confirmed that CYP27B1 variation associates with MS risk.

Cancer Associations

CYP27B1 variants have been studied across multiple cancer types. A prospective study of men found that genetic variation in vitamin D pathway genes (including CYP27B1) combined with higher vitamin D blood levels was associated with substantially lower risk of lethal prostate cancer. A separate study of men also linked vitamin D pathway variants to prostate cancer risk. A systematic review of non-small cell lung cancer (NSCLC, the most common form of lung cancer) found that CYP27B1 polymorphisms may serve as prognostic markers for survival, and a study of NSCLC patients found vitamin D pathway variants interact with smoking and vitamin D levels to influence risk.

Cardiovascular Disease

Several smaller studies have tied CYP27B1 variants to cardiovascular risk. A case-control study identified the CYP27B1 rs3782130 variant as a potential cardiovascular risk biomarker. A pilot study of people with cardiovascular disease found that CYP27B1 polymorphisms shape vitamin D metabolite levels and may contribute to disease risk. These signals are preliminary and need larger studies to confirm.

Bone Health and Fractures

A study of older adults found that a common functional variant in the CYP27B1 promoter region was associated with fracture risk. This suggests that even small genetic differences in how efficiently your body activates vitamin D can have downstream consequences for bone strength as you age.

Vitamin D-Dependent Rickets

Rare loss-of-function mutations affecting both inherited copies of CYP27B1 cause vitamin D-dependent rickets type 1A (VDDR1A), a severe childhood bone disease. A large case series, covering affected children across Turkey, identified common mutations and suggested a founder effect in that population. A milder form of the disease has been described with the p.Ala129Thr variant in a small case series. This is a monogenic disorder, which means it is driven by one gene, and it requires confirmatory genetic testing if there is a strong family history or clinical suspicion in a child.

Disease Associations at a Glance

Source: Bailey et al. 2007 (type 1 diabetes); Shui et al. 2012 (prostate cancer); Clifton-Bligh et al. 2010 (fracture risk).

What this means for you: a CYP27B1 risk variant does not predict disease on its own. It shifts your baseline odds, which makes the case for paying closer attention to the downstream markers (vitamin D status, blood sugar, autoimmune antibodies, bone density) that you can actually act on.

Why This Is a One-Time Test

Your CYP27B1 DNA does not change over your lifetime, so unlike a blood vitamin D level, this test only needs to be done once. The result is permanent. What changes over time is what you do with it, which is why this test is most useful as a starting point that guides ongoing tracking of vitamin D status, calcium, parathyroid function, and disease-specific markers.

Think of CYP27B1 as the genetic context for everything else you measure. Two people with the same vitamin D blood level may be activating it very differently inside their cells based on their genotype, and that may be why one of them feels fine on a standard supplement dose while the other does not.

What to Do With a Risk Variant

If your test reveals a risk variant, the most useful next step is to check what your gene is doing in real life. Measuring serum 25-hydroxyvitamin D tells you how much vitamin D is in circulation. Measuring serum 1,25-dihydroxyvitamin D tells you how much your body has actually activated. Looked at together, they give a functional read on whether your genotype is showing up in your physiology.

For variants linked to autoimmune disease risk, regular monitoring of thyroid function, blood glucose, and autoimmune antibodies makes sense, especially if there is a family history. For variants linked to bone health, prioritize bone density tracking and vitamin D adequacy as you age. If there is strong concern for vitamin D-dependent rickets in a child, the right next step is referral to a pediatric endocrinologist who can confirm the diagnosis and start treatment with activated vitamin D.

When Results Can Be Misleading

• Population-specific risk estimates: most CYP27B1 variants have been studied primarily in people of European ancestry, and the size of the risk shift may not translate equally across ancestries.
• Limited variant coverage: commercial genetic panels typically check a small number of well-studied variants, so a 'negative' result does not rule out rarer mutations the test does not look for.
• Modest effect sizes: carrying a risk variant is not a diagnosis, and most variants individually shift risk by a small amount. The test is one input into a larger picture, not a verdict.
• Sample contamination: genetic tests use buccal (cheek swab) or blood samples, and recent food, drink, or oral hygiene can occasionally interfere with sample quality, requiring a redraw.